{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T18:34:07Z","timestamp":1792089247176,"version":"4.4.0"},"reference-count":54,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.xphs.2025.104046","type":"journal-article","created":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T01:47:04Z","timestamp":1761788824000},"page":"104046","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Demonstration of in vitro-in vivo relationship (IVIVR) and virtual bioequivalence (VBE) between progesterone intravaginal rings using physiologically based pharmacokinetic (PBPK) modelling"],"prefix":"10.1016","volume":"115","author":[{"given":"Kanika","family":"Thakur","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8204-3623","authenticated-orcid":false,"given":"Ola","family":"Sternebring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-E","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-7405-6487","authenticated-orcid":false,"given":"Kevin","family":"Wyckoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5937-9973","authenticated-orcid":false,"given":"Iain","family":"Macdonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4227-7687","authenticated-orcid":false,"given":"Philippe","family":"Pinton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Paterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishna Chaitanya","family":"Telaprolu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Polak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.xphs.2025.104046_bib0001","doi-asserted-by":"crossref","first-page":"538","DOI":"10.3390\/pharmaceutics11100538","article-title":"In vitro methods for evaluating drug release of vaginal ring formulations\u2014a critical review","volume":"11","author":"Tietz","year":"2019","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.xphs.2025.104046_bib0002","series-title":"Vitro Drug Release Testing of Special Dosage Forms","first-page":"177","article-title":"Vaginal and intrauterine delivery systems","author":"Klein","year":"2019"},{"key":"10.1016\/j.xphs.2025.104046_bib0003","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jconrel.2019.10.015","article-title":"In vitro release testing methods for drug-releasing vaginal rings","volume":"313","author":"Boyd","year":"2019","journal-title":"J Control Release"},{"key":"10.1016\/j.xphs.2025.104046_bib0004","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.jconrel.2015.09.052","article-title":"In vitro\u2013in vivo correlation for complex non-oral drug products: where do we stand?","volume":"219","author":"Shen","year":"2015","journal-title":"J Control Release"},{"issue":"2","key":"10.1016\/j.xphs.2025.104046_bib0005","doi-asserted-by":"crossref","first-page":"255","DOI":"10.3390\/pharmaceutics13020255","article-title":"In vitro\u2013in vivo correlation (IVIVC) population modeling for the in silico bioequivalence of a long-acting release formulation of progesterone","volume":"13","author":"Tosca","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.xphs.2025.104046_bib0006","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejps.2017.02.029","article-title":"A survey on IVIVC\/IVIVR development in the pharmaceutical industry\u2013past experience and current perspectives","volume":"102","author":"Nguyen","year":"2017","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.xphs.2025.104046_bib0007","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/S0169-7161(00)18035-6","article-title":"33 Methods of establishing in vitro-in vivo relationships for modified release drug products","volume":"18","author":"Mauger","year":"2000","journal-title":"Handb Stat"},{"key":"10.1016\/j.xphs.2025.104046_bib0008","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1208\/s12248-020-00458-9","article-title":"In vitro dissolution profiles similarity assessment in support of drug product quality: what, how, when\u2014Workshop summary report","volume":"22","author":"Suarez-Sharp","year":"2020","journal-title":"AAPS J"},{"issue":"8","key":"10.1016\/j.xphs.2025.104046_bib0009","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1007\/s11095-022-03280-4","article-title":"The use of physiologically based pharmacokinetic analyses-in biopharmaceutics applications -regulatory and industry perspectives","volume":"39","author":"Anand","year":"2022","journal-title":"Pharm Res"},{"key":"10.1016\/j.xphs.2025.104046_bib0010","doi-asserted-by":"crossref","first-page":"223","DOI":"10.2147\/DDDT.S41401","article-title":"Jachowicz R.,et al. Generalized in vitro-in vivo relationship (IVIVR) model based on artificial neural networks","author":"Mendyk","year":"2013","journal-title":"Drug Des Dev Ther"},{"key":"10.1016\/j.xphs.2025.104046_bib0011","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.1007496","article-title":"A mechanistic physiologically based model to assess the effect of study design and modified physiology on formulation safe space for virtual bioequivalence of dermatological drug products","volume":"13","author":"Clarke","year":"2022","journal-title":"Front Pharmacol"},{"issue":"2","key":"10.1016\/j.xphs.2025.104046_bib0012","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s11095-022-03319-6","article-title":"Physiologically based pharmacokinetics modeling in biopharmaceutics: case studies for establishing the bioequivalence safe space for innovator and generic drugs","volume":"40","author":"Wu","year":"2023","journal-title":"Pharm Res"},{"issue":"5","key":"10.1016\/j.xphs.2025.104046_bib0013","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1002\/cpt.2356","article-title":"Zhao L. Physiologically-based pharmacokinetic modeling to support determination of bioequivalence for dermatological drug products: scientific and regulatory considerations","volume":"111","author":"Tsakalozou","year":"2022","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.xphs.2025.104046_bib0014","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s40495-016-0059-9","article-title":"Recent advances in development and application of physiologically-based pharmacokinetic (PBPK) models: a transition from academic curiosity to regulatory acceptance","volume":"2","author":"Jamei","year":"2016","journal-title":"Curr pharmacol rep"},{"issue":"2","key":"10.1016\/j.xphs.2025.104046_bib0015","first-page":"75","article-title":"Where do PBPK models stand in pharmacometrics and systems pharmacology?","volume":"9","author":"Jamei","year":"2020","journal-title":"CPT: Pharmacomet Syst Pharmacol"},{"key":"10.1016\/j.xphs.2025.104046_bib0016","doi-asserted-by":"crossref","first-page":"123273","DOI":"10.1016\/j.ijpharm.2023.123273","article-title":"A novel physiologically based pharmacokinetic model of rectal absorption, evaluated and verified using clinical data on 10 rectally administered drugs","volume":"643","author":"Dancik","year":"2023","journal-title":"Int J Pharm"},{"key":"10.1016\/j.xphs.2025.104046_bib0017","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.ejpb.2022.08.005","article-title":"Modelling and simulation approaches to support formulation optimization, clinical development and regulatory assessment of the topically applied formulations\u2013Nimesulide solution gel case study","volume":"178","author":"Mittapelly","year":"2022","journal-title":"Eur J Pharm Biopharm"},{"issue":"6","key":"10.1016\/j.xphs.2025.104046_bib0018","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1111\/bcp.16029","article-title":"Development and verification of mechanistic vaginal absorption and metabolism model to predict systemic exposure after vaginal ring and gel application","volume":"90","author":"Thakur","year":"2024","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.xphs.2025.104046_bib0019","doi-asserted-by":"crossref","first-page":"212","DOI":"10.3389\/fphar.2017.00212","article-title":"X., et al. Pharmacokinetic properties of three forms of vaginal progesterone administered in either single or multiple dose regimen in healthy post-menopausal Chinese women","volume":"8","author":"Wu","year":"2017","journal-title":"Front Pharmacol"},{"issue":"5","key":"10.1016\/j.xphs.2025.104046_bib0020","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1002\/psp4.12600","article-title":"Physiologically-based pharmacokinetic modeling to support bioequivalence and approval of generic products: A case for diclofenac sodium topical gel, 1","volume":"10","author":"Tsakalozou","year":"2021","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"issue":"4","key":"10.1016\/j.xphs.2025.104046_bib0021","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1002\/cpt.1364","article-title":"Innovation for generic drugs: science and research under the generic drug user fee amendments of 2012","volume":"105","author":"Lionberger","year":"2019","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.xphs.2025.104046_bib0022","unstructured":"USFDA, Guidance for industry statistical approaches to establishing bioequivalence, U.S.D.o.H.a.H.S.F.a.D.A.C.f.D.E.a.R. (CDER), Editor. 2021."},{"key":"10.1016\/j.xphs.2025.104046_bib0023","unstructured":"USFDA, The use of physiologically based pharmacokinetic analyses \u2014bopharmaceutics applications for oral drug product development, manufacturing changes, and controls guidance for industry, (CDER), Editor. 2020."},{"issue":"5","key":"10.1016\/j.xphs.2025.104046_bib0024","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1007\/s11095-006-9210-3","article-title":"Mechanistic approaches to volume of distribution predictions: understanding the processes","volume":"24","author":"Rodgers","year":"2007","journal-title":"Pharm Res"},{"issue":"6","key":"10.1016\/j.xphs.2025.104046_bib0025","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1002\/jps.20502","article-title":"Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions","volume":"95","author":"Rodgers","year":"2006","journal-title":"J Pharm Sci"},{"issue":"6","key":"10.1016\/j.xphs.2025.104046_bib0026","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1530\/eje.0.1330696","article-title":"Reincke M., et al. High-dose progesterone infusion in healthy males: evidence against antiglucocorticoid activity of progesterone","volume":"133","author":"Allolio","year":"1995","journal-title":"Euro J Endocrinol"},{"issue":"5","key":"10.1016\/j.xphs.2025.104046_bib0027","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1080\/15513815.2017.1354411","article-title":"Patil A.S. Characterization of maternal and fetal CYP3A-mediated progesterone metabolism","volume":"36","author":"Quinney","year":"2017","journal-title":"Fetal Pediatr Pathol"},{"issue":"1","key":"10.1016\/j.xphs.2025.104046_bib0028","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1006\/abbi.1997.0302","article-title":"Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes","volume":"346","author":"Yamazaki","year":"1997","journal-title":"Arch Biochem Biophys"},{"issue":"1","key":"10.1016\/j.xphs.2025.104046_bib0029","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/S0015-0282(16)56031-2","article-title":"Andrews M.C.,et al. The absorption of oral micronized progesterone: the effect of food, dose proportionality, and comparison with intramuscular progesterone","volume":"60","author":"Simon","year":"1993","journal-title":"Fertil Steril"},{"key":"10.1016\/j.xphs.2025.104046_bib0030","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.toxrep.2020.01.004","article-title":"Determination and prediction of permeability across intestinal epithelial cell monolayer of a diverse range of industrial chemicals\/drugs for estimation of oral absorption as a putative marker of hepatotoxicity","volume":"7","author":"Kamiya","year":"2020","journal-title":"Toxicol Rep"},{"issue":"4","key":"10.1016\/j.xphs.2025.104046_bib0031","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/S0015-0282(16)58226-0","article-title":"Sch\u00f6naueret L.M. Pharmacokinetics and endometrial effects of the vaginal administration of micronized progesterone in an oil-based solution to postmenopausal women","volume":"65","author":"Cicinelli","year":"1996","journal-title":"Fertil Steril"},{"issue":"9","key":"10.1016\/j.xphs.2025.104046_bib0032","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1021\/ie50537a062","article-title":"Liquid diffusivities. Viscosity of gases","volume":"46","author":"Scheibel","year":"1954","journal-title":"Ind Eng Chem"},{"issue":"4","key":"10.1016\/j.xphs.2025.104046_bib0033","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/0010-7824(92)90056-Y","article-title":"Progesterone-releasing vaginal rings for use in postpartum contraception. II. Pharmacokinetic profiles in women","volume":"45","author":"Landgren","year":"1992","journal-title":"Contraception"},{"issue":"5","key":"10.1016\/j.xphs.2025.104046_bib0034","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1208\/s12248-020-00480-x","article-title":"M. Considerations and caveats when applying global sensitivity analysis methods to physiologically based pharmacokinetic models","volume":"22","author":"Liu","year":"2020","journal-title":"AAPS J"},{"issue":"3","key":"10.1016\/j.xphs.2025.104046_bib0035","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1208\/s12248-010-9185-1","article-title":"DDSolver: an add-in program for modeling and comparison of drug dissolution profiles","volume":"12","author":"Zhang","year":"2010","journal-title":"AAPS J"},{"issue":"4","key":"10.1016\/j.xphs.2025.104046_bib0036","doi-asserted-by":"crossref","DOI":"10.1097\/GME.0000000000002148","article-title":"Evaluation of 28-day estradiol and progesterone vaginal rings in a phase 1 clinical pharmacokinetic study","volume":"30","author":"Hull","year":"2023","journal-title":"Menopause"},{"issue":"8","key":"10.1016\/j.xphs.2025.104046_bib0037","article-title":"A phase 1\/2, open-label, parallel group study to evaluate the safety and pharmacokinetics of DARE-HRT1 (80 \u03bcg estradiol\/4 mg progesterone and 160 \u03bcg estradiol\/8 mg progesterone intravaginal rings) over 12 weeks in healthy postmenopausal women","volume":"30","author":"Thurman","year":"2023","journal-title":"Menopause"},{"key":"10.1016\/j.xphs.2025.104046_bib0038","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.ejps.2016.10.036","article-title":"Pepin X., et al. IMI\u2013Oral biopharmaceutics tools project\u2013Evaluation of bottom-up PBPK prediction success part 2: an introduction to the simulation exercise and overview of results","volume":"96","author":"Margolskee","year":"2017","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.xphs.2025.104046_bib0039","doi-asserted-by":"crossref","first-page":"114293","DOI":"10.1016\/j.ejpb.2024.114293","article-title":"Bioequivalence risk assessment of oral formulations containing racemic ibuprofen through a chiral physiologically based pharmacokinetic model of ibuprofen enantiomers","volume":"199","author":"Reig-L\u00f3pez","year":"2024","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.xphs.2025.104046_bib0040","first-page":"405","article-title":"Intravenous infusion of progesterone in Human females: blood levels obtained and effect of labor","volume":"22","author":"Taubert","year":"1963","journal-title":"Obs Gynecol"},{"issue":"12","key":"10.1016\/j.xphs.2025.104046_bib0041","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1200\/JCO.1993.11.12.2417","article-title":"Phase I\/pharmacokinetic study of high-dose progesterone and doxorubicin","volume":"11","author":"Christen","year":"1993","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.xphs.2025.104046_bib0042","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1177\/0091270005276201","article-title":"Denson D.D. Steady-state serum concentrations of progesterone following continuous intravenous infusion in patients with acute moderate to severe traumatic brain injury","volume":"45","author":"Wright","year":"2005","journal-title":"J Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.xphs.2025.104046_bib0043","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/S0015-0282(16)54713-X","article-title":"Comparative bioavailability of orally and vaginally administered progesterone","volume":"56","author":"Norman","year":"1991","journal-title":"Fertil Steril"},{"issue":"3","key":"10.1016\/j.xphs.2025.104046_bib0044","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.maturitas.2005.11.005","article-title":"Pharmacokinetics of progesterone and its metabolites allopregnanolone and pregnanolone after oral administration of low-dose progesterone","volume":"54","author":"Andreen","year":"2006","journal-title":"Maturitas"},{"issue":"3","key":"10.1016\/j.xphs.2025.104046_bib0045","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S0015-0282(99)00553-1","article-title":"Comparison of the pharmacokinetics of crinone 8% administered vaginally versus Prometrium administered orally in postmenopausal women(3)","volume":"73","author":"Levine","year":"2000","journal-title":"Fertil Steril"},{"issue":"5","key":"10.1016\/j.xphs.2025.104046_bib0046","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/S0015-0282(16)48977-6","article-title":"Bioavailability of oral micronized progesterone","volume":"44","author":"Maxson","year":"1985","journal-title":"Fertil steril"},{"issue":"11","key":"10.1016\/j.xphs.2025.104046_bib0047","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1111\/j.1471-0528.1984.tb15086.x","article-title":"von Schoultz B. Serum levels of progesterone and some of its metabolites including deoxycorticosterone after oral and parenteral administration","volume":"91","author":"Ottoson","year":"1984","journal-title":"BJOG: Int J Obstet Gynaecol"},{"key":"10.1016\/j.xphs.2025.104046_bib0048","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.2147\/DDDT.S204624","article-title":"Deng C. Pharmacokinetics of hard micronized progesterone capsules via vaginal or oral route compared with soft micronized capsules in healthy postmenopausal women: a randomized open-label clinical study","author":"Wang","year":"2019","journal-title":"Drug Des Dev Ther"},{"issue":"11","key":"10.1016\/j.xphs.2025.104046_bib0049","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1093\/humrep\/dey288","article-title":"Prinz R. Effect on endometrial histology and pharmacokinetics of different dose regimens of progesterone vaginal pessaries, in comparison with progesterone vaginal gel and placebo","volume":"33","author":"Duijkers","year":"2018","journal-title":"Hum Reprod"},{"issue":"1","key":"10.1016\/j.xphs.2025.104046_bib0050","doi-asserted-by":"crossref","first-page":"eabk2901","DOI":"10.1126\/sciadv.abk2901","article-title":"Soh H.T. Real-time monitoring of drug pharmacokinetics within tumor tissue in live animals","volume":"8","author":"Seo","year":"2022","journal-title":"Sci adv"},{"issue":"2","key":"10.1016\/j.xphs.2025.104046_bib0051","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/0022-4731(87)90078-1","article-title":"Radioimmunoassay of plasma progesterone after oral administration of micronized progesterone","volume":"26","author":"Nahoul","year":"1987","journal-title":"J Steroid Biochem"},{"issue":"6217","key":"10.1016\/j.xphs.2025.104046_bib0052","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1136\/bmj.280.6217.825","article-title":"Absorption and metabolism of oral progesterone","volume":"280","author":"Whitehead","year":"1980","journal-title":"Br Med J"},{"key":"10.1016\/j.xphs.2025.104046_bib0053","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.ejps.2016.08.037","article-title":"Pharmacokinetic modeling of a gel-delivered dapivirine microbicide in humans","volume":"93","author":"Halwes","year":"2016","journal-title":"Eur J Pharm Sci"},{"issue":"3","key":"10.1016\/j.xphs.2025.104046_bib0054","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1002\/jps.2600790304","article-title":"Characterization of the barrier properties of mucosal membranes","volume":"79","author":"Corbo","year":"1990","journal-title":"J Pharm Sci"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354925005003?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354925005003?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T13:18:53Z","timestamp":1766582333000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354925005003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":54,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S0022354925005003"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2025.104046","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Demonstration of in vitro-in vivo relationship (IVIVR) and virtual bioequivalence (VBE) between progesterone intravaginal rings using physiologically based pharmacokinetic (PBPK) modelling","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2025.104046","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Pharmacists Association. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104046"}}